CCL20‐CCR6 Cytokine Network Facilitate Treg Activity in Advanced Grades and Metastatic Variants of Hepatocellular Carcinoma
暂无分享,去创建一个
[1] C. Sautès-Fridman,et al. The immune response in cancer: from immunology to pathology to immunotherapy , 2015, Virchows Archiv.
[2] Ye Zheng,et al. Regulatory T cell identity: formation and maintenance. , 2015, Trends in immunology.
[3] B. Zhu,et al. T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.
[4] Wei-min Li,et al. Treg‐specific demethylated region activity in isolated regulatory t lymphocytes is a surrogate for disease severity in hepatocellular carcinoma , 2015, IUBMB life.
[5] C. Feng,et al. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study , 2015, BMC Gastroenterology.
[6] Jie Ma,et al. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells. , 2015, Oncology reports.
[7] Adrian Y. S. Lee,et al. The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended? , 2015, Cytokine.
[8] Lixin Wei,et al. TGF-β Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization , 2015, Cellular Physiology and Biochemistry.
[9] A. Di Giannatale,et al. The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression , 2015, Front. Immunol..
[10] T. Welling,et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. , 2014, Gastroenterology.
[11] S. Aktaş,et al. Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours. , 2014, Hepato-Gastroenterology.
[12] Xiao-Fan Wang,et al. The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. , 2014, National science review.
[13] J. Wolchok,et al. The importance of animal models in tumor immunity and immunotherapy. , 2014, Current opinion in genetics & development.
[14] D. Kurtz,et al. Tracking cellular and immune therapies in cancer. , 2014, Advances in cancer research.
[15] Z. Liang,et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer , 2013, Oncogene.
[16] A. B. Lyons,et al. CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil? , 2013, Front. Immunol..
[17] R. Lamaita,et al. Immune Response Evaluation Through Determination of Type 1, Type 2, and Type 17 Patterns in Patients With Epithelial Ovarian Cancer , 2013, Reproductive Sciences.
[18] D. Busch,et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice , 2012, Hepatology.
[19] Haiyang Xie,et al. Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis , 2011, PloS one.
[20] Ke Wu,et al. IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer , 2011, The Journal of Immunology.
[21] Hong Wang,et al. Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice , 2011, PloS one.
[22] Ti Zhang,et al. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.
[23] Lin Bin. FOXP3~+ regulatory T cells , 2010 .
[24] Chuan-hai Zhang,et al. STAT 3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells , 2022 .